| Company Name: |
Jinan blalong chemical co. LTD
|
| Tel: |
2710913286@.com |
| Email: |
1513643261@qq.com |
| Products Intro: |
Product Name:Ivacaftor-d19
CAS:1413431-22-7
Purity:99% HPLC Package:50G;10G;1G;500MG;100MG
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:Ivacaftor-d19
CAS:1413431-22-7
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Ivacaftor-d19
CAS:1413431-22-7
Purity:95% Package:1mg
|
|
| | Ivacaftor-d19 Basic information |
| Product Name: | Ivacaftor-d19 | | Synonyms: | Ivacaftor-d19;Ivacaftor-D19Q: What is
Ivacaftor-D19 Q: What is the CAS Number of
Ivacaftor-D19;N-[2,4-bis[1,1-di(methyl-d3)ethyl-2,2,2-d3]-5-hydroxyphenyl-3d]-1,4-dihydro-4-oxo-3-quinolinecarboxamide | | CAS: | 1413431-22-7 | | MF: | C24H28N2O3 | | MW: | 392.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1413431-22-7.mol |  |
| | Ivacaftor-d19 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Acetonitrile:Methanol (1:1): soluble,DMSO: soluble | | form | A solid |
| | Ivacaftor-d19 Usage And Synthesis |
| Description | Ivacaftor-d19 is intended for use as an internal standard for the quantification of ivacaftor by GC- or LC-MS. Ivacaftor is an orally bioavailable potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) that improves chloride transport. It increases the forskolin-induced CFTR-mediated epithelial current in cells expressing the G551D missense mutation associated with severe cystic fibrosis by approximately 4-fold (EC50 = 100 nM) but has no effect on current in the absence of forskolin. Ivacaftor increases chloride secretion in cultured human cystic fibrosis bronchial epithelial cells carrying the G551D mutation on one allele and the common ΔF508 processing mutation on the other allele. It binds CFTR directly and leads to CFTR channel opening via an ATP-independent mechanism. Formulations containing ivacaftor have been used in the treatment of cystic fibrosis in patients carrying one or more mutations in the CFTR gene. |
| | Ivacaftor-d19 Preparation Products And Raw materials |
|